Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.

MLA

Delphine Hequet, et al. “Prospective, Multicenter French Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the Management of Early-Stage Breast Cancers.” PLoS ONE, vol. 12, no. 10, Jan. 2017, p. e0185753. EBSCOhost, https://doi.org/10.1371/journal.pone.0185753.

APA

Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff, Cyril Foa, Rémy Salmon, Aurélie Roulot, Florence Lerebours, Anne Salomon, Nadeem Ghali, Pascale Morel, Qianyi Li, Anne Cayre, … Roman Rouzier. (2017). Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. PLoS ONE, 12(10), e0185753. https://doi.org/10.1371/journal.pone.0185753

Chicago

Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, et al. 2017. “Prospective, Multicenter French Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the Management of Early-Stage Breast Cancers.” PLoS ONE 12 (10): e0185753. doi:10.1371/journal.pone.0185753.